CBD, huile de Cannabidiol, THC, médicaments à base de cannabis : le point santé [rYvhPCKRIWc]

CBD, huile de Cannabidiol, THC, médicaments à base de cannabis : le point santé [rYvhPCKRIWc]

| 1h 28m 28s | Video has closed captioning.

00:00 Présentation du chanvre et des cannabinoïdes 03:17 Le CBD et propriétés pharmacologiques 05:00 Extraction du CBD 05:30 Huiles de chanvre et CBD 06:52 Composés cancérigènes ? 07:36 Médicaments à base de cannabis 08:35 Effet d'un usage récréationnel du THC/Cannabis sur la santé 09:03 Usage thérapeutique du THC et/ou CBD ► Pour me suivre sur Facebook : ► Pour me suivre sur Twitter : @T_Fiolet ► Mon blog : Sources : ► Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242. doi:10.1001/jamapsychiatry.2015.1858 ► Winters KC, Lee C-YS. Likelihood of developing an alcohol and cannabis use disorder during youth: Association with recent use and age. Drug Alcohol Depend. 2008;92(1-3):239-247. ► Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2(3):244-268. doi:10.1037/1064-1297.2.3.244 ►Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120-130. doi:10.1016/j.drugalcdep.2010.11.004 ► VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019;94(9):1840-1851. doi:10.1016/j.mayocp.2019.01.003 ► Da Porto C, Decorti D, Natolino A. Potential oil yield, fatty acid composition, and oxidation stability of the hempseed oil from four Cannabis sativa L. cultivars. J Diet Suppl. 2015;12(1):1-10. doi:10.3109/19390211.2014.887601 ► ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 2017;103:1-36. doi:10.1007/978-3-319-45541-9_1 ► IARC Assessment. ► White CM. A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. J Clin Pharmacol. 2019;59(7):923-934. doi:10.1002/jcph.1387 ► Li J, Carvajal R, Bruner L, Kaminski NE. The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products. Food Chem Toxicol. 2021;157:112600. doi:10.1016/j.fct.2021.112600 ► Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. doi:10.1001/jama.2015.6358 ► Millar SA, Stone NL, Yates AS, O'Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018;9:1365. Published 2018 Nov 26. doi:10.3389/fphar.2018.01365 ► Kröger E, Dionne C E. Medical cannabis for chronic pain BMJ 2021; 374 :n1942 doi:10.1136/bmj.n1942 ► INSERM. Cannabinoïdes et système nerveux central : ► ► Yin AQ, Wang F, Zhang X. Integrating endocannabinoid signaling in the regulation of anxiety and depression. Acta Pharmacol Sin. 2019;40(3):336-341. doi:10.1038/s41401-018-0051-5 ► Australian Therapeutic Goods Administration. Review on the safety of low dose cannabidiol ► ► ► Freeman TP, Craft S, Wilson J, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2021;116(5):1000-1010. doi:10.1111/add.15253 ► American Cancer Society - Marijuana and Cancer ► Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436. doi:10.1016/S2215-0366(19)30048-3 #amazon cbd gummies 500mg #cbd gummies trial pack